

# Rajiv Dhand

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4129547/rajiv-dhand-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21  
papers

1,295  
citations

12  
h-index

24  
g-index

24  
ext. papers

1,608  
ext. citations

5.2  
avg. IF

5.37  
L-index

#	Paper	IF	Citations
21	Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. <i>Chest</i> , <b>2005</b> , 127, 335-71	5.3	530
20	Aerosol drug delivery: developments in device design and clinical use. <i>Lancet, The</i> , <b>2011</b> , 377, 1032-45	4.0	332
19	Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, 651-659	10.2	142
18	The role of nebulized therapy in the management of COPD: evidence and recommendations. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2012</b> , 9, 58-72	2	74
17	Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , <b>2020</b> , 33, 300-304	3.8	43
16	The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , <b>2020</b> , 33, 1-11	3.8	39
15	Asthma in Adult Patients with COVID-19. Prevalence and Risk of Severe Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 893-905	10.2	22
14	Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices. <i>Respiratory Care</i> , <b>2018</b> , 63, 833-839	2.1	18
13	Inhalation Therapy for Stable COPD: 20 Years of GOLD Reports. <i>Advances in Therapy</i> , <b>2020</b> , 37, 1812-1828	4.1	17
12	Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler. <i>International Journal of COPD</i> , <b>2019</b> , 14, 509-523	3	16
11	Aerosol therapy for asthma. <i>Current Opinion in Pulmonary Medicine</i> , <b>2000</b> , 6, 59-70	3	15
10	Inhaled Drug Therapy 2016: The Year in Review. <i>Respiratory Care</i> , <b>2017</b> , 62, 978-996	2.1	14
9	Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease. <i>Cleveland Clinic Journal of Medicine</i> , <b>2018</b> , 85, S19-S27	2.8	9
8	Effects of Inhaled Epoprostenol and Prone Positioning in Intubated Coronavirus Disease 2019 Patients With Refractory Hypoxemia <b>2020</b> , 2, e0307		7
7	Airborne Particulate Concentrations During and After Pulmonary Function Testing. <i>Chest</i> , <b>2021</b> , 159, 1570-1574	5.3	6
6	Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective. <i>Pulmonary Therapy</i> , <b>2021</b> , 7, 345-376	3	5
5	Maintenance Therapy with Nebulizers in Patients with Stable COPD: Need for Reevaluation. <i>Pulmonary Therapy</i> , <b>2020</b> , 6, 177-192	3	2

4	The Impact of Inhaler Device Regimen in Patients with Asthma or COPD. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 3033-3040.e1	5.4	2
3	COPD in Primary Care: Key Considerations for Optimized Management: Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease. <i>Journal of Family Practice</i> , <b>2018</b> , 67, S19-S27	0.2	2
2	Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease.. <i>International Journal of COPD</i> , <b>2022</b> , 17, 79-92	3	0
1	Aerosol delivery systems for treating obstructive airway diseases during the SARS-CoV-2 pandemic. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 2035-2039	3.7	0